Geode Capital Management LLC Purchases 13,812 Shares of Hologic, Inc. (NASDAQ:HOLX)

Geode Capital Management LLC grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 0.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,587,293 shares of the medical equipment provider's stock after purchasing an additional 13,812 shares during the period. Geode Capital Management LLC owned approximately 2.41% of Hologic worth $453,606,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Innealta Capital LLC purchased a new stake in shares of Hologic in the 2nd quarter valued at approximately $25,000. Wolff Wiese Magana LLC acquired a new stake in Hologic during the 3rd quarter valued at $25,000. Groupama Asset Managment lifted its holdings in shares of Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 2,999 shares in the last quarter. Sunbelt Securities Inc. acquired a new stake in shares of Hologic in the second quarter worth $37,000. Finally, First Horizon Advisors Inc. grew its holdings in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 134 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.75% of the stock is currently owned by company insiders.

Hologic Stock Down 1.9 %

Shares of NASDAQ HOLX traded down $1.44 during mid-day trading on Friday, reaching $73.65. 2,553,424 shares of the company traded hands, compared to its average volume of 1,626,827. The company's fifty day moving average is $79.32 and its two-hundred day moving average is $78.56. Hologic, Inc. has a fifty-two week low of $70.24 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The stock has a market cap of $16.71 billion, a PE ratio of 22.12, a price-to-earnings-growth ratio of 2.38 and a beta of 0.96.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same quarter last year, the company posted $0.89 earnings per share. The company's revenue for the quarter was up 4.5% compared to the same quarter last year. On average, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on HOLX shares. Wolfe Research assumed coverage on Hologic in a research note on Friday. They set a "peer perform" rating on the stock. UBS Group upped their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. lifted their target price on shares of Hologic from $92.00 to $94.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Needham & Company LLC restated a "buy" rating and set a $90.00 price target on shares of Hologic in a report on Tuesday. Finally, Evercore ISI increased their price objective on Hologic from $78.00 to $82.00 and gave the stock an "in-line" rating in a report on Tuesday, October 1st. Six investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $89.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.